地舒单抗联合鲑降钙素注射液治疗骨质疏松的效果  

Effect of Denosumab Combined with Calcitonin(Salmon)Injection in the Treatment of Osteoporosis

作　　者：吴亚 宋长志 徐磊 陈凯 WU Ya;SONG Changzhi;XU Lei;CHEN Kai(Department of Orthopedics,Yancheng NO.1 People's Hospital,Yancheng 224000,China;不详)

机构地区：[1]盐城市第一人民医院骨科,江苏盐城224000

出　　处：《中国医学创新》2025年第9期28-32,共5页Medical Innovation of China

摘　　要：目的:探究骨质疏松患者采用地舒单抗联合鲑降钙素注射液治疗的临床效果。方法:2022年1月—2023年1月开展研究,方案为双盲随机比对试验,抽取盐城市第一人民医院收治的80例骨质疏松患者,采用病历号抽签法区分为试验组与对照组,两组均40例。对照组采用鲑降钙素注射液肌内注射治疗。试验组在对照组方案基础上,增加地舒单抗治疗,给药方式为腹部皮下注射。比较两组治疗总有效率、骨密度水平、白介素-6(IL-6)水平、肿瘤坏死因子-α(TNF-α)水平、胰岛素样生长因子-1(IGF-1)水平、骨代谢标志物水平、不良反应发生率。结果:试验组治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗后试验组股骨颈、L_(1~4)、全髋的骨密度均高于对照组,差异均有统计学意义(P<0.05);治疗后试验组IL-6、TNF-α水平均低于对照组,IGF-1水平高于对照组,差异均有统计学意义(P<0.05);治疗后试验组甲状旁腺激素(PTH)、Ⅰ型羧基端交联端肽胶原(CTX)均低于对照组,25-羟基维生素D[25-(OH)D]高于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:骨质疏松患者采用地舒单抗联合鲑降钙素注射液治疗效果显著,可增加骨密度,改善炎症因子、生长因子及骨代谢标志物水平,用药安全性较高。Objective:To explore the clinical effect of Denosumab combined with Calcitonin(Salmon)Injection in patients with osteoporosis.Method:The study was conducted from January 2022 to January 2023.The protocol was a double-blind randomized comparison trial.80 osteoporosis patients admitted to Yancheng NO.1 People's Hospital were selected and divided into test group and control group by medical record number lottery method,with 40 cases in both groups.The control group was treated by intramuscular injection of Calcitonin(Salmon)Injection.On the basis of the control group,the test group was treated with Denosumab by subcutaneous injection in the abdomen.The total effective rate,bone mineral density,interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),insulin-like growth factor-1(IGF-1),markers of bone metabolism,and incidence of adverse effects were compared between the two groups.Result:The total effective rate of test group was higher than that of control group,the difference was statistically significant(P<0.05).After treatment,bone mineral density of femoral neck,L_(1-4)and hip in test group were higher than those in control group,with statistical significance(P<0.05).After treatment,the levels of IL-6 and TNF-αin test group were lower than those in control group,and the level of IGF-1 was higher than that in control group,with statistical significance(P<0.05).After treatment,parathyroid hormone(PTH),typeⅠcarboxyl terminal crosslinked terminal peptide collagen(CTX)in test group were lower than those of the control group,25-hydroxyvitamin D[25-(OH)D]was higher than that of the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse effects between the two groups(P>0.05).Conclusion:Denosumab combined with Calcitonin(Salmon)Injection can increase bone mineral density,improve the levels of inflammatory factors,growth factors and bone metabolic markers in patients with osteoporosis,and the drug safety is high.

关 键 词：地舒单抗 鲑降钙素注射液 骨质疏松 

分 类 号：R73[医药卫生—肿瘤]